This phase 3 trial demonstrated that the combination of tiragolumab and atezolizumab with chemotherapy significantly improved progression-free and overall survival compared to chemotherapy alone in patients with unresectable oesophageal squamous cell carcinoma. The treatment was well tolerated with manageable side effects, providing a promising first-line treatment option for this patient population. Atezolizumab + chemotherapy group was lacking.
Study
|
Randomised, double-blind, placebo-controlled, phase 3 trial [SKYSCRAPER-08] |
| Unresectable or metastatic oesophageal squamous cell carcinoma, treatment-naive patients |
| Tiragolumab (n=229) plus atezolizumab and chemotherapy vs placebo and chemotherapy (n=232)
|
Efficacy
|
ORR: 59.7% (tiragolumab group) vs 45.5% (placebo group) |
| mPFS: 6.2 mos vs 5.4 mos (HR 0.56 [0.45-0.70]) |
| mOS: 15.7 mos vs 11.1 mos (HR 0.70 [0.55-0.88])
|
Safety
|
Grade >=3 AEs: white blood cell count decrease (20% vs 15%), neutrophil count decrease (34% vs 34%), anaemia (8% vs 11%) |
| Serious AEs: pneumonia (7% vs 6%) |
| Treatment-related deaths: 3% vs 1%
|
Lancet Oncol 2026;27:103-115
http://doi.org/10.1016/S1470-2045(25)30480-1
Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026
